KIT and gastrointestinal stromal tumor: In the present study, we further confirmed that although various c-Kit wild-type SCLC cell lines, including NCI-H526, NCI-H889, and NCI-H1048, were treated with imatinib up to 10 μM, >90% cell viability was maintained, whereas the IC50 of imatinib was 0.03–0.3 μM in c-Kit-positive GIST cells in which imatinib is the standard of care (Supplementary Figure S4 and Supplementary Table S1).